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Introduction
Cancer is a major global health problem and is a leading cause of death both in developed and developing countries. Most commonly practiced therapies in patients target cancer cells by the use of non-specific and non-selective treatments that cause significant off target effects. In particular chemotherapy is the preferred clinical method for cancer treatment since the 1940s, despite its many side effects. Biological therapies are in limited use in augmenting standard therapies, but this approach has thus far not been effective enough to replace the traditional methods of chemotherapy in the majority of cancers. The shortcomings in efficacy and safety associated with the current treatment regimens emphasize the need for highly specific and targeted alternative therapies which could maximize patient survival and minimize the limitations of the existing strategies.
The discovery of the c-Myc gene has changed our fundamental understanding of malignancy and it is now well established that c-Myc is deregulated in the majority of cancers (1) .
Mechanistically, the basis of this association appears to stem from the plethora of roles played by c-Myc in regulating cell death, growth and proliferation, as well as in regulating important biochemical functions such as the uptake and metabolism of cellular glucose (2) . c-Myc therefore appears to act as a cellular master switch, controlling a network of oncogenes and tumour suppressor genes through a variety of signal transduction pathway molecules. Mutations in c-Myc or gross changes in its expression levels, clearly have the potential to derail the otherwise precise checkpoints that maintain cells in their normal quiescent state and lead to the development of cancer. Therapeutically, approaches that would allow the reprogramming and retuning of c-Myc activity within cancer cells are attractive strategies for disease control and prevention (3) . One such approach is the use of RNA interference (RNAi) technology. Recent 7 breakthroughs in RNAi technology have vastly improved our understanding of how gene expression can be specifically modulated and can be employed as a potential therapeutic tool (4-7). Harnessing small RNA molecules to silence genes involved in the development and growth of cancer cells is an important step forward in developing a new and target-focused cancer therapy (8) . The biggest challenge to the use of RNAi technology lies in achieving effective intracellular delivery of therapeutic molecules, in the form of either short interfering RNA (siRNA) or short hairpin RNA (shRNA) (9) . Recently, spherical nucleic acid-gold nanoparticle conjugates were shown to cross the blood brain barrier and induce apoptosis in glioma cells, thereby reducing tumour burden (10) . While the pre-formed 21 base siRNA duplexes are highly unstable, with a transient period of expression, shRNAs are more robust and better suited for long term effectiveness, due to their ability to produce siRNAs continuously within the cell and hence bring about prolonged knock-down of the target genes. Although a shRNA based approach would be ideal for cancer-related therapeutic development, they have thus far only been delivered effectively in vivo using viral vectors. However, with viral-based delivery it is important to bear in mind their potential immunogenicity and the risk of becoming pathogenic due to mutations. The idea of using a non-viral agent stems from its ability to mimic a viral function to infect cells, while avoiding the dangers of virus-associated pathogenesis. The use of non-viral transfecting agents has been proposed for several years because they are theoretically safer and easier to produce (11). However, their clinical success has been limited in the delivery of shRNA due to low transfection efficiency, difficulties of integration and unstable expression.
Currently, polyethyleneimine (PEI) is the most widely used non-viral agent and is considered the gold standard in vitro (12) . The major drawback of PEI as a transfecting agent is its cytotoxicity, and the observed correlation between increased transfection efficacy with increased molecular weight and concentration of PEI (13) (14) (15) (16) (17) makes it a difficult proposition to improve efficiency without its deleterious effect on cells. We have previously demonstrated that anchoring multiple PEI chains to PGMA nanoparticles can dramatically decrease their toxicity even at higher concentrations, whilst achieving efficient nanoparticle endocytosis (16) . In the current study, various types of nucleic acids, designed to target cancer-related genes, were tested in different cancer cell lines after conjugation to these nanoparticles. shRNAs of c-Myc oncogene were selected to test the in vivo efficacy of this biological drug complex in targeting knock down of the oncogene and related signaling cascades, thus triggering suppression of growth in established mouse models of colorectal and breast cancer.
Materials and Methods

Preparation and characterization of the PEI-PGMA NPs
The PEI-PGMA NPs were prepared following the procedure outlined by Evans et al (16) with the magnetic cores synthesized as per the procedure outlined by sun et. al (18) . The NPs were characterized using TEM (JOEL 2100) at 120kV, Dynamic light scattering for size and surface charge, and fluorescence spectrometry. Nitrogen concentration was obtained using elemental analysis of the NPs before and after PEI attachment. Nitrogen concentration was determined to be 765μM at a NP concentration of 1mg/ml. The NPs were superparamagnetic as determined by SQUID magnetometry, as there was no hysteresis at 300K (with specific saturation magnetization of 6 emu g -1 ), and the relaxivity r 2 of the NP was determined, based on the iron content inside the polymer, to be 340 s -1 mM -1 Fe. The NPs were centrifuged (16000g, 30 min), the supernatant was removed and the NP pellet was resuspended in 20mM HEPES buffer containing 150mM NaCl. They were then sterilized under UV for 20 min and mixed with DNA in different ratios and incubated at room temperature for 45min. To assess optimal binding, a gel and GIPZ non-silencing shRNA (RHS4346), which was used as negative control to rule out offtarget effects (Open Biosystems, USA). In the case of the shRNAs, the best out of the four which showed maximum knock down was selected for in vivo experiments. Mimics and antimiRs were purchased from Exiqon, Denmark. Cells were seeded in complete media (RPMI for Jurkat and DMEM for all other cell lines, with 10% FBS) in 24 well plates in triplicates at a density of 2 × times and data transformed using arcsine transformation method before statistical analysis.
RNA isolation and Quantitative Real Time PCR analysis
At the end of each time point, media was removed and cells were scraped off in TRIzol reagent (Invitrogen,USA). RNA from homogenized tissue samples as well as cell lysates were isolated using RNAeasy kit (Qiagen, USA) and RNA concentrations were measured using nanodrop spectrometer (Thermo-scientific). A 260nm/280nm absorption ratio of 2.0 confirmed the RNA to be pure and protein free. The quality of RNA was also checked using 1% agarose gel electrophoresis. One microgram of RNA was transcribed to cDNA using random primers and further used for both SYBR green assay and Taqman gene expression assay of all the genes.
Total RNA was DNase-treated and one microgram RNA was transcribed to cDNA using RT-PCR Reagents kit (Applied Biosystems). Quantitative PCR analysis was performed using SYBR ® Green PCR master mix following standard MIQE protocols as well as TaqMan® Table S1 ). The fold expressions of particular genes are represented as log 10 2 -Δ Δ CT . Real Time StatMiner® Software was used for data analysis. This software performs parametric, non-parametric and paired tests for relative quantification of gene expression, as well as a 2-way ANOVA for two-factor differential expression analysis.
Immunoblot analysis
Total cellular protein from all cell lines transfected with respective miRNA mimics/knock down and shRNAs was extracted after 72hrs using lysis buffer containing 1x protease inhibitor cocktail (Calbiochem USA). Protein concentrations were measured by the Bradford (Sigma) method and equal amounts (~25-30 μg) of cellular extract/lysate were separated on 10-12% SDS-PAGE gels and electro-transferred onto nitrocellulose membranes (Millipore, Bedford, MA, USA).
Membranes were blocked with 5% non-fat milk for 1h at room temperature, before incubation with appropriate primary antibodies for c-Myc, β-catenin, GAPDH, p53 or β-actin (1:3000) overnight at 4°C. Membranes were then incubated with 1:10,000 horseradish peroxidase- following exposure onto X-ray film. All human and mouse primary antibodies used were raised in rabbit with a dilution of 1:4000 for all the westerns and 1:50 for ICC. The secondary antibodies were raised in mouse/donkey with a dilution factor of 1:10,000 for western and 1:200 for ICC.
In vivo studies
All animal models were used strictly in accordance with the animal ethical committees of the participating institutes, CCMB and Cardiff University, and were housed in the transgenic facilities of the respective institutes. Two types of animal models were used in the study. The 
Fourier Transform Infrared Spectroscopy (FTIR)
To analyze the toxicity of the nanoparticles in vivo, mice were divided into 4 groups consisting of 5 mice each. The different cohorts received 0, 250, 500 or 1000g daily dose of NPs by oral gavage for a period of 21 days in this sub-chronic toxicity study. The control cohort (no NPs) was treated with just buffer. Following treatment, animals were sacrificed as per the ethics guidelines and tissues (liver, kidney, lung, spleen) were removed and immediately frozen in liquid nitrogen. They were freeze-dried using a Labconco system (Missouri, USA) and crushed in asceptic conditions. The freeze dried pellets were analyzed for the characteristic peaks that represent intactness of macromolecular organization in the organs. Scanning was performed using a Bruker Vertex-70 FTIR spectrometer, with the ATR mode in the range of 400-4000 cm -1 to obtain the characteristic peaks.
In vitro Cytotoxicity assay of PEI-PGMA-NPs
Adherent (HEK293, MCF7 and MDA-MB 231), semi-adherent (COLO205) and non-adherent 
Statistical analysis
The data of percentage cells transfected was subjected to arsine transformation, as the values ranged from 4-98% and the transformed data was subjected to statistical analysis as per the factorial completely randomized design, with cell type taken as one factor and transfection agent type taken as the other. In vivo data obtained are shown as mean values ± s.e.m. Significant difference between means were performed using two tailed students t-test. N is the number of independent animals used in all cases with p<0.05.
Results
Cytotoxicity and Bio-distribution studies did not show NP toxicity effects in vitro or in vivo
The ability of a non-viral transfection agent (Fig. 1A and Supplementary Fig. S1 ) to bind plasmid DNA, and in turn induce RNAi efficiently, is primarily governed by its ability to successfully bind nucleic acids (RNAs, small oligos and plasmid DNA encoding shRNAs) at high loading concentrations. Using gel retardation assays, the ratios [PEI-PGMA(N): DNA(D)] of 4:1 and 25:1 (weight/volume (W/V)) were found to be optimum for binding oligos and plasmid DNAs respectively. These ratios were ideal for achieving high transfection efficiency in all types of cell lines (Fig. 1B) . Once the binding ratios were optimized, S2 ). This study ascertained that NP concentrations up to 300g/ml did not induce any significant cytotoxicity on the cell lines investigated. A major concern of all nanoparticulate agents in translational research is their potential toxicity in vivo and as a result it was important to carefully assess the bio-distribution and toxicity profile of our NPs in vivo before validating therapeutic efficacy. The reticuloendothelial system (RES) is primarily involved in the identification, biodegradation and removal of foreign particulate matter in the body. A thorough investigation of the fate of the key organs involved in RES after treatment with the NPs was performed using standard techniques such as Fourier Transform Infrared spectroscopy (FTIR) and Liver function tests (21) . Histological data obtained by H&E staining of control tissue (no NPs) compared with tissue from mice acutely treated for 6 weeks on weekdays with a dose of 1250 μg (or 50 mg/kg) NPs showed integrity in liver, spleen and kidney ( Supplementary Fig.   S3A ). This was further supported by FTIR analysis of the respective organs following treatment with the same dose of the NPs (Supplementary Fig. S3B) 
control and NP-treated mice showed no significant difference with respect to the enzymes alanine transaminase or alkaline phosphatase following prolonged treatment with 1250 μg NPs (Supplementary Fig. S3C ).
Efficient induction of RNA interference in vitro
Achieving high levels of transfection using non-viral agents remains a challenge in most semiadherent and non-adherent cell lines, due to the lack of syndecans, unlike in adherent cells (22) . immuno-blotting ( Fig. 2A and Supplementary Fig. S4 ). The ability of our NPs to transfect a large DNA construct was tested by using a pGIPZ vector encoding shRNA against the ubiquitous GAPDH gene as a positive control and scrambled shRNA as negative control.
Successful transfection of the cells was indicated by the knock down of the target gene in all three cell lines investigated (Fig. 2B) . Similarly, knockdown of the target oncogene c-Myc was observed when pGIPZ vector coding for c-Myc shRNA was used, demonstrating the effective knockdown of the target c-Myc oncogene as verified by q-PCR, immuno-blotting and immunocytochemistry (Fig. 2C) .
Suppression of autochthonous mammary tumours
In the Blg-cre Brca2/p53 conditional knockout breast cancer model, mice develop spontaneous mammary tumours between 6 and 15 months of age (Fig. 3A) . Injections to the periphery of tumours were carried out using c-Myc shRNA ( p G I P Z v e c t o r ) c o m p l e x e d w i t h PEI-PGMA (25:1, N:D) in a cohort of 6 mice, along with appropriate control cohorts (n=6), to test the penetrability and distribution of the NPs in the tumour and the efficacy of treatment (Fig.   3B ). Tumours treated with shRNA bound to the NPs showed a markedly reduced tumour growth rate compared to controls (Fig. 3C) . The median survival of the cohort treated with cMyc shRNA-NP complex was over 30 days, compared to control cohorts that had median survivals of between 10 and 14 days (Fig. 3D) . A concomitant 30-fold reduction in c-Myc levels was confirmed by q-PCR, immuno-blotting analysis and immunohistochemistry for the cMyc shRNA bound to the NP treatment group in comparison to both wild type and untreated cohorts ( Fig. 3E-G) . Importantly, although injection was done at the tumour periphery, equal distribution of NPs was observed throughout the tumour core and extended periphery by Fig. S5A & B) . In addition, no trace of the NPs was observed in off-target organs even at the end of treatment, as assessed by fluorescence ( Supplementary Fig. S5C and D) .
Suppression of colorectal cancer model
In our colorectal cancer model, induction of Apc loss by tamoxifen and β-naphthoflavone injection results in the development of a widespread, aggressive c-Myc-dependent 'crypt progenitor' phenotype. This mimics early tumour development along the entire length of the small intestine and results in the death of the animals within 7 to 10 days. We hypothesized that the high buffering capacity of the multiple PEI chains on the NPs would render significant protection to the shRNA from the harsh environment of the gastrointestinal tract. Additionally, the adhesive property of the cationic polymer with the proteoglycan-coated proteins, coupled with the ability of PEI to effect endocytosis, would result in significant transfection in the distal large intestine. Therapy was orally administered to a cohort of 6 mice, and the response was again compa red with approriate control cohorts (n=6). Confocal imaging tracked the presence of the NPs all along the intestinal tract, with higher doses localized within the distal large intestine and comparatively only trace amounts observed in the small intestine and proximal large intestine (Fig. 4A) . Despite the disproportionate presence of the NPs in these tissues, effective c-Myc transcript and protein level reduction was observed by both q-PCR and western blotting across these major components of the gastrointestinal tract (Fig. 4C) . The high levels of NPs present in the large intestine is most likely a result of the 40 days) when compared to control cohorts, where median survival was less than 15 days in all cases (Fig. 4B) . Immunohistochemical analysis at various time points throughout the treatment reflected a progressive reduction in the expression levels of the c-Myc protein (Fig. 4D) .
Additionally, re-localization of β-catenin from nucleus to cytoplasm was observed during treatment, indicating a return to a non-wnt-deregulated state (Fig. 5A) . Site triggering of the NPs in the distal large intestine was shown by significant expression of turbo-FP co-localized with the NPs as assessed by confocal analysis (Fig. 5B) , as well as ex vivo multispectral imaging of the entire gut of the mouse following oral delivery (Fig. 5C ). Protein ratios were calculated based on densitometric quantification and were carried out using the GeneTools program (SynGene), with β-actin used for normalization ( Supplementary Fig. S6 ).
Discussion
Cancer therapy has been moving through a slow process of development, hitherto hindered by limitations in drug targeting technologies. The focus on cancer drug development has shifted from toxic and non-specific chemotherapeutic drugs to non-toxic and target-specific biological drugs with reduced side effects. The discovery of RNAi technology has significantly enhanced our understanding of how gene expression can be modulated as a potential therapeutic tool and high throughput screening method for targets against many cancers, although delivery of such therapy to autochthonous tumors still remains largely elusive (25) 
thus leading to sub-optimal treatment and potential relapse (26) . In this report, through both in vitro and in vivo studies, we have demonstrated the effective use of a simple non-viral nanoparticle, at a non-cytotoxic level, for the targeted delivery of nucleic acid molecules as biological drug cargos into different cancer tissues.
The successful transfection of the nanoparticles presented in this study is the result of PEI's ability to associate with membrane proteins, which in turn results in endocytosis of the PEI-conjugated nanoparticles. The propensity of PEI to act as a "proton sponge" allows for endosomal escape of its incorporated polyplexes. Following endocytosis, natural acidification within the endosome protonates PEI, inducing chloride ion influx, osmotic swelling and destabilization of the vesicle, leading to the release of the polyplex into the cytoplasm. Grafting multiple PEI chains on to a macromolecular core significantly enhanced the NPs capability to transfect, protect and deliver DNA/RNA molecules. The glycidyl methacrylate units, located in the "loops" of the PGMA core with multiple free epoxy groups, serve as reactive sites for the subsequent attachment of the PEI sub-units. The major difference between this method and the traditional method of anchoring PEI to the surface of a nanoparticle lies in the mobility of the epoxy functional groups located on the PGMA core. This increased mobility ensures better access to the epoxide functional groups, resulting in a 2-3 fold greater grafting density when compared to a monolayer of epoxy groups on a nanoparticle surface of similar dimension (27) . 
reactions of epoxy groups are quite universal, affording ease of attachment of the amino functionalized PEI and carboxylic functionalized RhB. In addition, the epoxy groups of the polymer can cross-link to provide structural integrity to the core. This renders the NPs as multimodal, with rhodamine B allowing for fluorescence imaging and magnetite for MRI contrast, thus providing suitability for use in both in vitro and in vivo studies.
Our in vitro studies showed that nucleic acids conjugated to NPs enhanced transfection efficiency and knockdown or recovery of various oncogenes and tumour suppressor genes in a number of cell lines. Using our NPs, microRNAs, anti-miRs (in the form of short oligos) and larger plasmid DNAs encoding shRNAs against targeted oncogenes/tumour suppressor genes were transfected into different cancer lines at high levels of efficiency, similar to those observed with viral agents. RNAi effects of shRNAs, antimiRs and mimics were evident with the efficient knock down and modulation of their respective targets. PEI-PGMA can act as a proton sponge which delays acidification and fusion with lysosome osmotic swelling and finally the rupture of some of the endosomes will in turn allow the escape of these NP-DNA complexes into the cytosol (28) . returned the small intestine to a near normal state, the effect of which was translated as markedly increased survival in the treatment cohort. This anti-cancer drug cargo thus promises an efficient bio-therapeutic regime for currently undruggable targets at problematic sites without obvious cytotoxicity. This observation has great implications for the treatment of solid tumours at their natural site of origin. A key factor that will contribute towards the successful translation of this platform will be the development of a robust, scalable production of the nanoparticle formulations in a good manufacturing practice facility, with further control over particle size distribution as described in previous polymer formulation reports (29) . In the present case, we believe this is achievable by fine-tuning the emulsion polymerization process. Although we demonstrate a proof of principle, our approach would be further enhanced by the development of moieties which would enable targeted, site specific delivery so as to avoid off-target effects.
In conclusion, we have demonstrated that we can use macromolecular grafting approaches to design efficient non-viral formulations that have in vivo capacity to deliver long term effective RNAi therapy against cancer. Furthermore, this work also demonstrates in-site delivery of a biological drug, for effective accumulation to therapeutic levels, the most desirable and preferred method for translation from bench to the bedside in cancer therapy. 
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